Related references
Note: Only part of the references are listed.Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink et al.
LANCET INFECTIOUS DISEASES (2021)
Population Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
Nao Kawaguchi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia
Luzelena Caro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
Takayuki Katsube et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
James A. Karlowsky et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
Krystyna M. Kazmierczak et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects
Keith A. Rodvold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
Akinobu Ito et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function
Takayuki Katsube et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung
Keith A. Rodvold et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence
Jared L. Crandon et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia
Shawn H. MacVane et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
T. W. Felton et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia
T. P. Lodise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid Focus on Antibacterial Agents
Keith A. Rodvold et al.
CLINICAL PHARMACOKINETICS (2011)
Interpretation of antibiotic concentration ratios measured in epithelial lining fluid
Sungmin Kiem et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia
MH Scheetz et al.
PHARMACOTHERAPY (2006)
Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia
E Boselli et al.
CRITICAL CARE MEDICINE (2003)
Share Paper
